NASDAQ: GILD $82 Billion Large-Cap. Nasdaq 100. S&P 500. Health Care Sector. Biotech & Pharma Industry. 5 Year Return 38%. 1 Year Return 2%. 2020 YTD Return 3%. Negative 5 year, 1 year & YTD returns. 3.4% dividend yield. 15 total dividend payments. Since Earnings 14%. "Possible" Death Cross chart pattern.
The 52 Week Low is $61.52 set on Wed, Oct 2, 2019.
The 52 Week High is $85.67 set on Thu, Apr 30, 2020.
The All-Time High is $122.40 set on Tue, Jun 23, 2015.
Earnings Per Share
Price To Earnings Ratio
Dividend Payment Date
Gilead Sciences trades on the NASDAQ. GILD's market cap is 78.0 Billion.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite acquisition and pending Forty-Seven acquisition boost Gilead's exposure to cell therapy and noncell therapy in oncology.